Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 39.27 Million SEK | 49.12% |
| 2022 | 28.97 Million SEK | -19.57% |
| 2021 | 36.01 Million SEK | 908.67% |
| 2020 | -4.45 Million SEK | -108.13% |
| 2019 | 54.78 Million SEK | -0.09% |
| 2018 | 54.83 Million SEK | 0.89% |
| 2017 | 54.35 Million SEK | 15.42% |
| 2016 | 47.09 Million SEK | 117.97% |
| 2015 | 21.6 Million SEK | -18.66% |
| 2014 | 26.55 Million SEK | 132.23% |
| 2013 | -82.39 Million SEK | -504.87% |
| 2012 | 20.35 Million SEK | 18.54% |
| 2011 | 17.16 Million SEK | -15.57% |
| 2010 | 20.33 Million SEK | 317.64% |
| 2009 | -9.34 Million SEK | -1.56% |
| 2008 | -9.19 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 18.7 Million SEK | 90.82% |
| 2024 Q3 | -278.9 Million SEK | -8815.63% |
| 2024 Q2 | 3.2 Million SEK | -82.89% |
| 2023 Q3 | 7.9 Million SEK | -9.2% |
| 2023 Q4 | 9.8 Million SEK | 24.05% |
| 2023 FY | 43.2 Million SEK | 49.12% |
| 2023 Q1 | 12.1 Million SEK | 20.16% |
| 2023 Q2 | 8.7 Million SEK | -28.1% |
| 2022 Q1 | 17.3 Million SEK | 25.2% |
| 2022 Q3 | 3.6 Million SEK | -28.0% |
| 2022 FY | 28.97 Million SEK | -19.57% |
| 2022 Q4 | 10.07 Million SEK | 179.72% |
| 2022 Q2 | 5 Million SEK | -71.1% |
| 2021 Q3 | 13 Million SEK | 465.22% |
| 2021 Q2 | 2.3 Million SEK | -66.18% |
| 2021 Q4 | 13.81 Million SEK | 6.29% |
| 2021 FY | 36.01 Million SEK | 908.67% |
| 2021 Q1 | 6.8 Million SEK | 116.34% |
| 2020 Q4 | -41.62 Million SEK | -277.14% |
| 2020 Q1 | 15.2 Million SEK | 0.5% |
| 2020 Q2 | -3 Million SEK | -119.74% |
| 2020 FY | -4.45 Million SEK | -108.13% |
| 2020 Q3 | 23.5 Million SEK | 883.33% |
| 2019 Q3 | 32.3 Million SEK | 447.46% |
| 2019 Q4 | 15.12 Million SEK | -53.18% |
| 2019 Q1 | 16.7 Million SEK | 386.17% |
| 2019 FY | 54.78 Million SEK | -0.09% |
| 2019 Q2 | 5.9 Million SEK | -64.67% |
| 2018 Q4 | 3.43 Million SEK | -73.16% |
| 2018 FY | 54.83 Million SEK | 0.89% |
| 2018 Q3 | 12.8 Million SEK | -35.35% |
| 2018 Q2 | 19.8 Million SEK | 5.32% |
| 2018 Q1 | 18.8 Million SEK | 26.58% |
| 2017 Q2 | -700 Thousand SEK | -105.83% |
| 2017 Q1 | 12 Million SEK | 829.51% |
| 2017 Q3 | 28.2 Million SEK | 4128.57% |
| 2017 Q4 | 14.85 Million SEK | -47.33% |
| 2017 FY | 54.35 Million SEK | 15.42% |
| 2016 Q2 | 12.6 Million SEK | 50.0% |
| 2016 Q3 | 24.8 Million SEK | 96.83% |
| 2016 Q4 | 1.29 Million SEK | -94.79% |
| 2016 Q1 | 8.4 Million SEK | 1290.73% |
| 2016 FY | 47.09 Million SEK | 117.97% |
| 2015 Q3 | 8.9 Million SEK | 178.13% |
| 2015 Q1 | 8.9 Million SEK | 26.08% |
| 2015 Q4 | 604 Thousand SEK | -93.21% |
| 2015 Q2 | 3.2 Million SEK | -64.04% |
| 2015 FY | 21.6 Million SEK | -18.66% |
| 2014 Q2 | 3.2 Million SEK | -49.21% |
| 2014 Q4 | 7.05 Million SEK | -29.41% |
| 2014 FY | 26.55 Million SEK | 132.23% |
| 2014 Q1 | 6.3 Million SEK | 93.61% |
| 2014 Q3 | 10 Million SEK | 212.5% |
| 2013 FY | -82.39 Million SEK | -504.87% |
| 2013 Q2 | 5.55 Million SEK | 1015.66% |
| 2013 Q4 | 3.25 Million SEK | 103.55% |
| 2013 Q3 | -91.7 Million SEK | -1750.47% |
| 2013 Q1 | 498 Thousand SEK | -91.71% |
| 2012 Q2 | -8.29 Million SEK | -283.74% |
| 2012 Q4 | 6 Million SEK | 291.66% |
| 2012 Q1 | 4.51 Million SEK | 6.44% |
| 2012 FY | 20.35 Million SEK | 18.54% |
| 2012 Q3 | 1.53 Million SEK | 118.5% |
| 2011 Q4 | 4.24 Million SEK | -23.31% |
| 2011 Q2 | 1.41 Million SEK | -76.26% |
| 2011 Q1 | 5.97 Million SEK | 70.24% |
| 2011 FY | 17.16 Million SEK | -15.57% |
| 2011 Q3 | 5.53 Million SEK | 289.71% |
| 2010 Q4 | 3.51 Million SEK | -16.8% |
| 2010 FY | 20.33 Million SEK | 317.64% |
| 2010 Q1 | 4.71 Million SEK | 0.0% |
| 2010 Q3 | 4.22 Million SEK | -46.49% |
| 2010 Q2 | 7.88 Million SEK | 67.22% |
| 2009 FY | -9.34 Million SEK | -1.56% |
| 2008 FY | -9.19 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 150.636% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 86.936% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 86.936% |
| Arcoma AB | 4.66 Million SEK | -742.704% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 129.765% |
| BICO Group AB (publ) | -618.3 Million SEK | 106.351% |
| CellaVision AB (publ) | 167.05 Million SEK | 76.492% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 159.56% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 232.796% |
| C-Rad AB (publ) | 44.24 Million SEK | 11.242% |
| Duearity AB (publ) | -25.76 Million SEK | 252.428% |
| Dignitana AB (publ) | -15.02 Million SEK | 361.347% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 141.424% |
| Getinge AB (publ) | 3.81 Billion SEK | 98.97% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 157.374% |
| Iconovo AB (publ) | -45.77 Million SEK | 185.786% |
| Integrum AB (publ) | 6.51 Million SEK | -503.009% |
| Luxbright AB (publ) | -25.8 Million SEK | 252.183% |
| Mentice AB (publ) | -679 Thousand SEK | 5883.505% |
| OssDsign AB (publ) | -91.95 Million SEK | 142.705% |
| Paxman AB (publ) | 12.61 Million SEK | -211.197% |
| Promimic AB (publ) | -9.11 Million SEK | 530.687% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 123.278% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 172.804% |
| ScandiDos AB (publ) | -13.48 Million SEK | 391.256% |
| Sectra AB (publ) | 518.49 Million SEK | 92.426% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 159.911% |
| Senzime AB (publ) | -133.74 Million SEK | 129.362% |
| SpectraCure AB (publ) | -21.35 Million SEK | 283.926% |
| Stille AB | 44.95 Million SEK | 12.64% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 101.094% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | -1.984% |